MARKET

NIKI

NIKI

NIKI BIOSOLUTIONS INC,
NASDAQ
2.030
-0.050
-2.40%
Pre Market: 2.030 0 0.00% 04:37 10/21 EDT
OPEN
2.070
PREV CLOSE
2.080
HIGH
2.140
LOW
1.900
VOLUME
20
TURNOVER
0
52 WEEK HIGH
17.20
52 WEEK LOW
1.900
MARKET CAP
1.65M
P/E (TTM)
-1.0948
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 12h ago
Weekly Report: what happened at NIKI last week (1012-1016)?
Weekly Report · 1d ago
Niki BioSolutions' DiamiR Biosciences Subsidiary To Perform Apolipoprotein E Genotyping On Plasma Samples From Global Alzheimer’s Platform Foundation Bio-Hermes-002 Trial Group
Benzinga · 6d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/13 21:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/12 12:05
Weekly Report: what happened at NIKI last week (1005-1009)?
Weekly Report · 10/12 10:10
Niki BioSolutions Launches At-the-Market Stock Offering
TipRanks · 10/09 21:29
Niki BioSolutions Enters At The Market Offering Agreement On October 9, 2026; May Sell Common Stock Up To $1.40M Aggregate Maximum Offering Price
Benzinga · 10/09 21:26
More
About NIKI
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.

Webull offers Aptorum Group Ltd stock information, including NASDAQ: NIKI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NIKI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NIKI stock methods without spending real money on the virtual paper trading platform.